A
AEON Biopharma, Inc. (AEON)
ASE – Real Time Price. Currency in USD
0.72
+0.03 (4.62%)
At close: Jun 26, 2026, 4:00 PM EDT
0.70
-0.02 (-2.47%)
After-hours: Jun 26, 2026, 7:36 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.72
+0.03 (4.62%)
At close: Jun 26, 2026, 4:00 PM EDT
0.70
-0.02 (-2.47%)
After-hours: Jun 26, 2026, 7:36 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $6.2M significantly exceed its total debt $2.6M, ensuring strong financial flexibility
Total current assets $6.6M are just enough to cover Total current liabilities $6.7M, indicating tight liquidity
Debt-to-equity ratio (-0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$2.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.99 | 6.05 | 6.0 | |
| Quick ratio | 0.99 | 5.63 | 6.0 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.30 | 1.04 | 7.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 4.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -68K | -99K | -97K | -78K | -78K |
| Operating Income | -48M | -53M | -28M | -17M | -19M |
| Net Income | -53M | -385M | 42M | -39M | -60M |
| EBITDA | -48M | -53M | -28M | -17M | -19M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 45 | 5.5 |
| Next quarter | N/A | 30.77 | 5.5 |
| Current year | N/A | 73.42 | 5.5 |
| Next year | N/A | -2780 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 68.24 | 94.47 | 44.06 | 10 |
| Y/Y | 999 | -229.65 | -112.71 | 66.69 | 5.5 |
| 3y average | 999 | -238.08 | 138.46 | 13.01 | 7.3 |
| 5y average | 999 | 45441.52 | N/A | -252.59 | 5.5 |
| Weighted average score | 7.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |